Expert Interview
Discussing Paradigm Therapeutics' acquisition of Amicus Therapeutics' SD-101 (developing investigational cream as a whole-body therapy in all forms of EB) after failure to meet primary and key goals in the Phase 3 ESSENCE clinical trial
Ticker(s): PARADIGM BIOPHARMACEURICALS, FOLDInstitution: Cincinnati Children’s Hospital
- Pediatric Dermatologist who specializes in medical and procedural dermatology
- Did a year of research studying vascular anomalies at Boston Children’s Hospital during medical school at Tufts University
- Manages 5 patients with DEB
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
